Table 1.
Visit plan
| Measures | Baseline | Day 2 | Day 14 | Day 30 | Day 60 | Day 90 |
| Demographics | x | |||||
| History of present illness | x | |||||
| mRS | x | x | x | x | x | x |
| History | x | |||||
| Medication | x | x | x | x | x | |
| NIHSS | x | x | x | x | ||
| Head CT | x | |||||
| Head MRI | x | |||||
| ASPECT | x | |||||
| Laboratory examination∗ | x | x | ||||
| Electrocardiograph | x | |||||
| Inclusion and exclusion criteria | x | |||||
| Informed consent | x | |||||
| Randomisation | x | |||||
| Injection | x | |||||
| Compliance | x | x | x | x | ||
| Special laboratory test | x | x | x | |||
| TOAST classification | x | |||||
| OCSP classification | x | |||||
| EQ-5D | x | x | x | |||
| MMSE | x | x | ||||
| MoCA | x | x | ||||
| Soft capsules | x | |||||
| AE/SAE | x | x | x | x | x |
*Including at least test of blood glucose, blood routine examination (count of platelet), and renal and liver function (alanine transaminase, aspartate aminotransferase and creatinine).
AE, adverse event; ASPECT, Alberta Stroke Program Early CT Score; EQ-5D, EuroQol 5D; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OCSP, Oxfordshire Community Stroke Programme; SAE, serious adverse event; TOAST, Trial of Org 10172 in Acute Stroke Treatment.